Skip to main navigation
  • OUR COMPANY
    • Our Purpose
    • Our Leadership
    • Our Locations
  • OUR FOCUS
    • The Problem
    • Uterine Fibroids
    • Endometriosis
    • Prostate Cancer
    • Infertility
  • OUR SCIENCE
    • Pipeline
    • Relugolix Combination Therapy
    • MVT-602
  • OUR MEDICINE
  • OUR ADVOCACY
    • Forward Together
  • JOIN THE TEAM
    • Our Culture
    • Our Benefits
    • Open Positions
  • Investors & Media
    • Company Overview
    • News & Events
      • Press Releases
      • Events
      • Presentations
    • Stock Information
      • Stock Quote & Chart
      • Historical Price Lookup
      • Analyst Coverage
    • Financials & Filings
      • SEC Filings
    • Corporate Governance
      • Board of Directors
      • Documents & Charters
      • Committee Composition
      • Expanded Access
    • Email Alerts
  • Contact Us
  • Twitter
  • LinkedIn

Documents & Charters

Documents & Charters

Governance Documents
Business Conduct and Ethics
Bye-laws
California Declaration of Compliance
Corporate Governance Guidelines
General Certificate of Conformance (GCC) with Consumer Product Safety Improvement Act
Information for Vermont Prescribers of Prescription Drugs (Long Form)
Information for Vermont Prescribers of Prescription Drugs (Short Form)
Healthcare Compliance Program
Open Door Policy for Reporting Complaints Regarding Accounting and Auditing Matters
Process for Shareholder Communications with the Board of Directors
Wholesale Acquisition Cost Information for Colorado Prescribers
Committee Charters
Audit Committee Charter
Compensation Committee Charter
Nominating and Corporate Governance Committee Charter
Proxy Materials
Notice and Proxy Statement for 2020 Annual Shareholders General Meeting
Annual Report on Form 10K for the Fiscal Year Ended March 31, 2020

Toolkit

Print Page
RSS Feeds
Email Alerts
Contact
Search
  • OUR COMPANY
    • Our Purpose
    • Our Leadership
    • Our Locations
  • OUR FOCUS
    • The Problem
    • Uterine Fibroids
    • Endometriosis
    • Prostate Cancer
    • Infertility
  • OUR SCIENCE
    • Pipeline
    • Relugolix Combination Therapy
    • MVT-602
  • OUR MEDICINE
  • OUR ADVOCACY
    • Forward Together
  • JOIN THE TEAM
    • Our Culture
    • Our Benefits
    • Open Positions
  • Investors & Media
    • Company Overview
    • News & Events
    • Stock Information
    • Financials & Filings
    • Corporate Governance
    • Email Alerts
  • Contact Us
© 2021 Myovant Sciences GmbH. All rights reserved.
Terms of Use Privacy Policy Cookie Policy